Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Vose

Showing results (81-90 of 140) with videos related to

Pageof 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphomaJ M Vose, M Crump, H Lazarus, et al.
Stem Cells (Dayton, Ohio)|July 1, 1995
Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trialsC L Bennett, S L George, J M Vose, et al.
Leukemia & Lymphoma|May 16, 2000
Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphomaJ M Vose, D Colcher, L Gobar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2006
Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group ExperienceA K Ganti, D D Weisenburger, L M Smith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2009
The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma ProjectJ Suzumiya, K Ohshima, K Tamura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphomaJ M Vose, B K Link, M L Grossbard, et al.
Blood|April 1, 1993
Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignanciesS N Rabinowe, D Neuberg, P J Bierman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1991
CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable toxicityJ M Vose, P J Bierman, J R Anderson, et al.
The New England Journal of Medicine|June 20, 1991
Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancerJ Nemunaitis, S N Rabinowe, J W Singer, et al.
Plant, Cell & Environment|November 4, 2006
Adjustments in hydraulic architecture of Pinus palustris maintain similar stomatal conductance in xeric and mesic habitatsR N Addington, L A Donovan, R J Mitchell, et al.
Pageof 14

Showing results (81-90 of 140) with videos related to

Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphomaJ M Vose, M Crump, H Lazarus, et al.
Stem Cells (Dayton, Ohio)|July 1, 1995
Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trialsC L Bennett, S L George, J M Vose, et al.
Leukemia & Lymphoma|May 16, 2000
Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphomaJ M Vose, D Colcher, L Gobar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2006
Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group ExperienceA K Ganti, D D Weisenburger, L M Smith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2009
The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma ProjectJ Suzumiya, K Ohshima, K Tamura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphomaJ M Vose, B K Link, M L Grossbard, et al.
Blood|April 1, 1993
Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignanciesS N Rabinowe, D Neuberg, P J Bierman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1991
CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable toxicityJ M Vose, P J Bierman, J R Anderson, et al.
The New England Journal of Medicine|June 20, 1991
Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancerJ Nemunaitis, S N Rabinowe, J W Singer, et al.
Plant, Cell & Environment|November 4, 2006
Adjustments in hydraulic architecture of Pinus palustris maintain similar stomatal conductance in xeric and mesic habitatsR N Addington, L A Donovan, R J Mitchell, et al.
Pageof 14